A Baltimore company is racing to unlock the secret to staying young. The doctor in charge of the effort believes his research has him on track to live to 150.

The Johns Hopkins Emerging Technology Center is home to a biotech company that’s bringing jobs to Baltimore. It’s using supercomputers to study diseases, like cancer, and come up with a way to prevent them.

There’s nothing ordinary about Dr. Alex Zhavoronkov. The CEO of Insilicone Medicine limits his sleep, diet and social life all in an effort to live longer.

His anti-aging research includes taking over 100 drugs and supplements every day.

“We are living longer, healthier. We are stretching that horizon. Why not try to stretch it further? I think it’s more harmful to do nothing than to try something that doesn’t have that many side effects,” Zhavoronkov said.

Zhavoronkov believes his best bet at doubling his lifespan is a supercomputer. He founded Insilicone Medicine to determine how to develop drugs programmed to prevent conditions like heart disease, cancer and Alzheimer’s.

“To develop artificial intelligence systems that recognize those complex patterns and can lead to solutions to some of the age-related diseases and hopefully aging itself,” Zhavoronkov said.

Zhavoronkov anchored the 33 employee endeavor in Baltimore, which he considers a bio-tech goldmine.

“Some of the world’s best talent is located here. It’s also much cheaper than anywhere else in the states when you do a cost-benefit analysis looking for talent and price, so it’s optimal,” Zhavoronkov said.

Hopkins students said it’s rare to find artificial intelligence endeavors like Zhavoronkov in Baltimore. They’re excited to get in on the ground floor.

“What’s special about computers is that they’re able to see things that people can’t see. They’re able to mine the data,” said Michael Scarlett, with Insilicone Medicine.

While the coders carry out their job in the computer lab, Zhavoronkov is combining their discoveries with his own self-experimentation to determine how to postpone the inevitable death as long as possible.

“There’s a huge pipeline of commercial projects that’s like a Pandora’s Box that’s ready to open and bring a lot of longevity dividends,” Zhavoronkov said.

If researchers figure out the formula for an anti-aging pill, some people may not live long enough to try it. Zhavoronkov estimates it would take up to 40 years to get a drug like that to market.